<DOC>
	<DOCNO>NCT00240682</DOCNO>
	<brief_summary>The purpose study determine whether cetuximab effective treatment locally advance metastatic squamous cell carcinoma skin express EGFR .</brief_summary>
	<brief_title>Study Cetuximab Squamous Cell Carcinoma Skin Expressing EGFR</brief_title>
	<detailed_description>Patients locally advance metastatic squamous cell carcinoma ( SCC ) skin often bad responder conventional chemotherapy include cisplatin . The investigation EGFR expression may allow identify new molecular target novel therapeutic strategy patient locally advance metastatic SCC skin . Several publication literature primary lesion one publication metastatic lesion show EGFR express 80-90 % SCC skin . Immunohistochemistry study perform Gustave Roussy Institute confirm data : find over-expression EGFR 90 % patient metastatic disease . These result favor investigation cetuximab patient locally advance metastatic SCC skin express EGFR . Cetuximab monoclonal antibody target EGFR administer weekly intravenous route ; may prescribe hospital patient locally advance metastatic SCC skin express EGFR . Due low occurrence locally advance metastatic SCC skin , multicenter trial require .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histological SCC skin expressing ( IHC ) moderately highly EGFR ( ++ +++ , semiquantitative scale ) . Locally advanced metastatic SCC skin suitable local surgery document progression . Presence least one measurable target lesion RECIST criterion . At least one lesion accessible biopsy . ECOG Performance status &lt; 2 . Life expectancy &gt; 3 month . Age &gt; 18 year . Normal hematological ( Neutrophils &gt; 1.5x109 cells/l , platelet &gt; 100x109 cells/l ) , hepatic ( bilirubin &lt; 1.5 time upper limit normal range ( ULN ) ; alkaline phosphatase transaminases &lt; 5 x UNL case hepatic metastasis &lt; 2.5 x UNL absence hepatic metastasis ) renal ( serum creatinine &lt; 150 micromol/L ) function . Written informed consent . In case second tumor , except carcinoma cervix adequately treat basal squamous cell skin carcinoma , possibility include patient may discuss principal investigator . Prior chemotherapy Prior radiotherapy &lt; 1 month . Prior therapy agent target EGFR Unstable systemic disease active uncontrolled infection . Patients ( male female ) use effective contraception reproductive potential . Females pregnant lactating . Women child bear potential must negative serum urine pregnancy test prior start cycle treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Carcinoma , Squamous Cell</keyword>
	<keyword>Skin</keyword>
	<keyword>cetuximab</keyword>
	<keyword>epidermal growth factor receptor</keyword>
</DOC>